Separate phase III CVOTs of GLP1R agonists are currently being conducted in people living with heart failure with preserved ejection fraction and in those with obesity
Gut bacteria cannot break it down, which means zero gas production, zero bloating, and zero of the cramping that fermentable fibers can cause
"So people might soon start thinking about that as a longer term option, and as the overall costs of GLP-1 drugs come down, they will become easier to prescribe as chronic medications," he says
10.1016/j.neuro.2018.05.001 100 JosephsK
It seems that many effects of AKT/mTOR signaling on the immune system and the aging process are mediated through the activation of STAT3 signaling
Physical effects typically follow later, sometime between 6-8 weeks of continued use